Cure My Disease

Don't miss your cure!

 Log in / Sign up

Grape juice vs. heart disease: a metabolic showdown

NCT ID NCT07777341

Knowledge-focused Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This trial tests whether drinking 400 mL of red grape juice daily for three weeks alters the blood metabolome—the collection of small molecules in blood—in people with chronic coronary artery disease. Participants alternate between a grape juice period and a period without polyphenol-rich foods. The goal is to see if grape polyphenols influence pathways related to lipids, carbohydrates, and energy production, offering a non-alcoholic way to support cardiovascular health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Red grape juice
What this could lead to
If red grape juice changes blood markers in a beneficial way, it could point toward dietary strategies to support heart health without alcohol.
What could go wrong
This is a small, early-stage study focused on biological markers, not clinical outcomes. Effects may be modest or not translate to real-world heart benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

46 to 69 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 46 and 69 years. * Established chronic coronary artery disease, defined by at least one of the following: * Acute myocardial infarction occurring more than 30 days before enrollment; * Angiographic evidence of ≥50% stenosis in one or more epicardial coronary arteries; * Previous percutaneous coronary intervention (PCI); * Previous coronary artery bypass grafting (CABG). * BMI \<30 kg/m². * Absence of: * Angina symptoms; * Dyspnea. Exclusion Criteria: * Use of antibiotics within 8 weeks before study enrollment. * Heart failure, NYHA functional class ≥ II. * Renal insufficiency, defined as creatinine clearance \<30 mL/min, calculated using the Cockcroft-Gault equation. * Hepatic insufficiency, defined by: * Thrombocytopenia; * Reduced serum albumin; * Prolonged prothrombin time. * Cancer. * Inflammatory bowel disease. * Obstructive biliary disease. * History of digestive tract surgery, including: * Cholecystectomy; * Gastrectomy; * Colectomy. * Diabetes mellitus. * Use of antidiabetic medications. * Hypertriglyceridemia. * Use of illicit drugs. * Habitual consumption of wine or other alcoholic beverages. * Unstable angina. * Moderate valvular heart disease. * Chagas disease. * Permanent pacemaker implantation. * Chronic obstructive pulmonary disease (COPD). * Aortic aneurysm. * Aortic ectasia measuring \<40 mm.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary arterial disease (CAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary arterial disease (CAD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Incor - Instituto do Coração HCFMUSP

    RECRUITING

    São Paulo, São Paulo, 05403-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.